Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults

Policy # 00059
Original Effective Date: 01/28/2002
Current Effective Date: 06/12/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer is addressed separately in medical policy 00054.

Note: Hematopoietic Cell Transplantation in the Treatment of Germ Cell Tumors is addressed separately in medical policy 00056.

Note: Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma is addressed separately in medical policy 00063.

Note: Hematopoietic Cell Transplantation for Solid Tumors of Childhood is addressed separately in medical policy 00064.

Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers autologous or allogeneic hematopoietic cell transplant (HCT) for miscellaneous solid tumors in adults including, but not limited to, the following malignancies to be investigational.*

- Lung cancer, any histology
- Colon cancer
- Rectal cancer
- Pancreatic cancer
- Stomach cancer
- Esophageal cancer
- Gall bladder cancer
Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults

Policy # 00059
Original Effective Date: 01/28/2002
Current Effective Date: 06/12/2023

- Cancer of the bile duct
- Renal cell cancer
- Cervical cancer
- Uterine cancer
- Cancer of the fallopian tubes
- Prostate cancer
- Nasopharyngeal cancer
- Paranasal sinus cancer
- Neuroendocrine tumors
- Soft tissue sarcomas
- Thyroid tumors
- Tumors of the thymus
- Tumors of unknown primary origin
- Malignant melanoma

**Background/Overview**

Though cancer incidence along with overall mortality has been declining in the United States, certain population groups continue to have an increased risk of cancer progression and mortality due to social, economic, and environmental disadvantages. The National Cancer Institute has published statistics on cancer disparities in relation to various criteria including specific racial and ethnic groups, gender, and geography. Some key incidence and mortality statistics in the United States are as follows: incidence rates of lung, colorectal, and cervical cancers are increased in rural Appalachia compared to urban areas; American Indians/Alaska Natives have increased mortality rates from kidney, liver, and intrahepatic bile duct cancer compared to other racial and ethnic groups; Black men are twice as likely to die of prostate cancer than White men.

**Hematopoietic Cell Transplantation**

Hematopoietic cell transplantation (HCT) is a procedure in which hematopoietic stem cells are intravenously infused to restore bone marrow and immune function in cancer patients who receive bone marrow-toxic doses of cytotoxic drugs with or without whole-body radiotherapy. Hematopoietic stem cells may be obtained from the transplant recipient (autologous HCT) or a donor.
Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults

Policy # 00059
Original Effective Date: 01/28/2002
Current Effective Date: 06/12/2023

(allogeneic HCT [allo-HCT]). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates.

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT. In allogeneic stem cell transplantation, immunologic compatibility between donor and patient is a critical factor for achieving a successful outcome. Compatibility is established by typing of human leukocyte antigens (HLA) using cellular, serologic, or molecular techniques. HLA refers to the gene complex expressed at the HLA-A, -B, and -DR (antigen-D related) loci on each arm of chromosome 6. An acceptable donor will match the patient at all or most of the HLA loci.

**Conditioning for Hematopoietic Cell Transplantation**

**Conventional Conditioning**
The conventional (“classical”) practice of allo-HCT involves the administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to cause bone marrow ablation in the recipient. The beneficial treatment effect of this procedure is due to a combination of the initial eradication of malignant cells and subsequent graft-versus-malignancy effect mediated by non-self-immunologic effector cells. While the slower graft-versus-malignancy effect is considered the potentially curative component, it may be overwhelmed by existing disease in the absence of pretransplant conditioning. Intense conditioning regimens are limited to patients who are sufficiently medically fit to tolerate substantial adverse effects. These include opportunistic infections secondary to loss of endogenous bone marrow function and organ damage or failure caused by cytotoxic drugs. Subsequent to graft infusion in allo-HCT, immunosuppressant drugs are required to minimize graft rejection and graft-versus-host disease (GVHD), which increases susceptibility to opportunistic infections.

The success of autologous HCT is predicated on the potential of cytotoxic chemotherapy, with or without radiotherapy, to eradicate cancerous cells from the blood and bone marrow. This permits subsequent engraftment and repopulation of the bone marrow with presumably normal hematopoietic stem cells obtained from the patient before undergoing bone marrow ablation. Therefore, autologous HCT is typically performed as consolidation therapy when the patient’s disease is in complete remission. Patients who undergo autologous HCT are also susceptible to chemotherapy-related toxicities and opportunistic infections before engraftment, but not GVHD.
Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation

Reduced-intensity conditioning (RIC) refers to the pretransplant use of lower doses of cytotoxic drugs or less intense regimens of radiotherapy than are used in traditional full-dose myeloablative conditioning treatments. Although the definition of RIC is variable, with numerous versions employed, all regimens seek to balance the competing effects of relapse due to residual disease and non-relapse mortality. The goal of RIC is to reduce disease burden and to minimize associated treatment-related morbidity and non-relapse mortality in the period during which the beneficial graft-versus-malignancy effect of allogeneic transplantation develops. RIC regimens range from nearly total myeloablative to minimally myeloablative with lymphoablation, with intensity tailored to specific diseases and patient condition. Patients who undergo RIC with allo-HCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism. In this review, the term RIC will refer to all conditioning regimens intended to be nonmyeloablative.

Hematopoietic Cell Transplantation in Solid Tumors in Adults

HCT is an established treatment for certain hematologic malignancies. Its use in solid tumors is less well established, although it has been investigated for a variety of solid tumors. With the advent of nonmyeloablative allogeneic transplant, interest has shifted to exploring the generation of alloreactivity to metastatic solid tumors via a graft-versus-tumor effect of donor-derived T cells.

HCT as a treatment for ovarian cancer, germ cell tumors, ependymoma, or malignant glioma is addressed separately (medical policies 00054, 00056, and 00063, respectively). HCT as a treatment for breast cancer is not addressed. This medical policy collectively addresses other solid tumors of adults for which HCT has been investigated, including lung cancer, malignant melanoma, tumors of the gastrointestinal tract (affecting the colon, rectum, pancreas, stomach, esophagus, gallbladder, or bile duct), male and female genitourinary systems (eg, renal cell carcinoma, prostate cancer, cervical cancer, uterine cancer, fallopian tube cancer), tumors of the head and neck, soft tissue sarcoma, thyroid tumors, tumors of the thymus, and tumors of unknown primary origin.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code
Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults

Policy #  00059
Original Effective Date:  01/28/2002
Current Effective Date:  06/12/2023

of Federal Regulation, Title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Hematopoietic cell transplantation (HCT) is an established treatment for certain hematologic malignancies and has been investigated for a variety of adult solid tumors. Interest continues in exploring nonmyeloablative allogeneic HCT (allo-HCT) for a graft-versus-tumor effect of donor-derived T-cells in metastatic solid tumors.

Summary of Evidence

Autologous Hematopoietic Cell Transplantation
For individuals who have adult soft tissue sarcomas who receive autologous HCT, the evidence includes 2 randomized controlled trials (RCTs), a number of phase 2 single-arm studies (some of which have been summarized in a systematic review), and a retrospective registry study. Relevant outcomes are overall survival (OS), disease-specific survival, and treatment-related mortality and morbidity. Although a small phase 2 RCT reported longer survival for patients treated with autologous HCT than with standard chemotherapy, this trial did not show an overall survival benefit with HCT. An RCT from 2019 also showed no survival benefits with autologous HCT. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have small cell lung cancer who receive autologous HCT, the evidence includes several RCTs, and systematic reviews of these studies. Relevant outcomes are OS, disease-specific survival, and treatment-related mortality and morbidity. Studies have not reported increased OS for patients with small-cell lung cancer treated with autologous HCT. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults

Policy #  00059
Original Effective Date:  01/28/2002
Current Effective Date:  06/12/2023

Allogeneic Hematopoietic Cell Transplantation
For individuals who have renal cell carcinoma, colorectal cancer, pancreatic cancer, or nasopharyngeal cancer who receive allo-HCT, the evidence includes small single-arm series. Relevant outcomes are OS, disease-specific survival, and treatment-related mortality and morbidity. The evidence for allo-HCT to treat renal cell carcinoma, colorectal cancer, pancreatic cancer, and nasopharyngeal cancer has been limited to small case series. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information
Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in ‘Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

National Comprehensive Cancer Network
Current National Comprehensive Cancer Network guidelines on the tumors addressed in this evidence review do not discuss hematopoietic cell transplantation (HCT) as a treatment option.

American Society for Blood and Marrow Transplantation
In 2015, the American Society for Blood and Marrow Transplantation (now referred to as the American Society for Transplantation and Cellular Therapy) issued guidelines related to indications for autologous and allogeneic HCT. The guidelines were updated in 2020. The tumors addressed herein for which the Society has provided recommendations are listed in Table 1.

Table 1. Recommendations for Use of Autologous and Allogeneic Hematopoietic Cell Transplantation

<table>
<thead>
<tr>
<th>Condition</th>
<th>Treatment Option</th>
<th>2015 Recommendation</th>
<th>2020 Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ewing sarcoma, high-risk</td>
<td>Allogeneic HCT</td>
<td>Not generally recommended</td>
<td>Developmental</td>
</tr>
</tbody>
</table>
Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults

Policy # 00059
Original Effective Date: 01/28/2002
Current Effective Date: 06/12/2023

<table>
<thead>
<tr>
<th>Renal cancer, metastatic</th>
<th>Autologous HCT</th>
<th>Standard of care, clinical evidence available</th>
<th>Standard of care, clinical evidence available</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Allogeneic HCT</td>
<td>Developmental</td>
<td>Developmental</td>
</tr>
</tbody>
</table>

| Autologous HCT | Not generally recommended | Not generally recommended |

HCT: hematopoietic cell transplantation.

**U.S. Preventive Services Task Force Recommendations**
Not applicable.

**Medicare National Coverage**
The Centers for Medicare & Medicaid Services currently have the following national noncoverage decision on autologous stem cell transplantation: “Insufficient data exist to establish definite conclusions regarding the efficacy of AuSCT [autologous stem cell transplantation] for the following condition[s]: Solid tumors (other than neuroblastoma).”

**Ongoing and Unpublished Clinical Trials**
Some currently ongoing and unpublished trials that might influence this review are listed in Table 2.

**Table 2. Summary of Key Trials**

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT04530487</td>
<td>Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults</td>
<td>40</td>
<td>May 2025</td>
</tr>
</tbody>
</table>
Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults

Policy # 00059
Original Effective Date: 01/28/2002
Current Effective Date: 06/12/2023

NCT04937842  Efficacy and Safety of Radiotherapy or Chemotherapy Combined with Microtransplantation in the Treatment of Advanced and Relapsed Solid Tumors  60  June 2025

NCT01505569  Alkylator-Intense Conditioning Followed by Autologous Transplantation for Patients with High Risk or Relapsed Solid or CNS Tumors  20  March 2024

NCT: national clinical trial.

References

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Policy # 00059
Original Effective Date: 01/28/2002
Current Effective Date: 06/12/2023


Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults

Policy # 00059
Original Effective Date: 01/28/2002
Current Effective Date: 06/12/2023


Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults

Policy # 00059
Original Effective Date: 01/28/2002
Current Effective Date: 06/12/2023


Policy History
Original Effective Date: 01/28/2002
Current Effective Date: 06/12/2023
12/06/2001 Medical Policy Committee review
01/28/2002 Managed Care Advisory Council approval
03/31/2004 Medical Director review
05/07/2004 Medical Director review
05/18/2004 Medical Policy Committee review. Format revision. High-Dose Chemotherapy and Hematopoietic Stem Cell Support for Miscellaneous Solid Tumors in Adults policy developed separately from current HDC with Hematopoietic Stem Cell Support policy. No substance change to policy.
06/28/2004 Managed Care Advisory Council approval
07/12/2006 Medical Director review

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults

Policy # 00059
Original Effective Date: 01/28/2002
Current Effective Date: 06/12/2023

07/19/2006 Medical Policy Committee approval. Format revision including addition of FDA and or other governmental regulatory approval and rationale/source. Coverage eligibility is unchanged.
06/04/2008 Medical Director review
06/18/2008 Medical Policy Committee approval. Coverage eligibility is unchanged.
06/04/2009 Medical Director review
06/17/2009 Medical Policy Committee approval. Changed title from “High-Dose Chemotherapy and Hematopoietic Stem Cell Support for Miscellaneous Solid Tumors in Adults” to “High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Miscellaneous Solid Tumors in Adults.” Coverage eligibility is unchanged.
05/04/2023 Medical Policy Committee review
05/10/2023 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 05/2024

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2022 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults

Policy # 00059
Original Effective Date: 01/28/2002
Current Effective Date: 06/12/2023

contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>38204, 38205, 38206, 38207, 38208, 38209, 38210, 38211, 38212, 38213, 38214, 38215, 38230, 38232, 38240, 38241, 38242, 38243</td>
</tr>
<tr>
<td>HCPCS</td>
<td>S2140, S2142, S2150</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.
Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults

Policy # 00059
Original Effective Date: 01/28/2002
Current Effective Date: 06/12/2023

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.